In a randomized, placebo-controlled phase 2a clinical trial, Roxadustat transiently and moderately increased endogenous EPO and reduced hepcidin level in nondialysis-dependent (NDD) CKD patients with an adverse events rate similar to placebo during the (up to) 12-week follow-up period (8). The gene discussed is HAMP; the disease is chronic kidney disease.